Selected research
Market Structure
Global Pulmonary Hypertension Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Pulmonary Hypertension Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Pulmonary Hypertension Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Pulmonary Hypertension Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Pulmonary Hypertension Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Pulmonary Hypertension Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Pulmonary Hypertension Drug include Biolab Sanus Farmaceutica Ltda., Hanmi Pharmaceuticals, Co. Ltd., Ikaria Inc., Proreo Pharma AG, Vectura Group plc, Vicore Pharma AB, Bayer AG and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Pulmonary Hypertension Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Pulmonary Hypertension Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Pulmonary Hypertension Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pulmonary Hypertension Drug market size, projected growth trends, production technologies, key applications, and end-use industries.
Pulmonary Hypertension Drug Segment by Company
Biolab Sanus Farmaceutica Ltda.
Hanmi Pharmaceuticals, Co. Ltd.
Ikaria Inc.
Proreo Pharma AG
Vectura Group plc
Vicore Pharma AB
Bayer AG
Sanofi
Pulmonary Hypertension Drug Segment by Type
IK-3001
Riociguat
Sildenafil Citrate IMD
SAR-407899
IK-7002
Others
Pulmonary Hypertension Drug Segment by Application
Clinic
Hospital
Others
Pulmonary Hypertension Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Hypertension Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Hypertension Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Hypertension Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Pulmonary Hypertension Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pulmonary Hypertension Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Pulmonary Hypertension Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Pulmonary Hypertension Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- IK-3001
- Riociguat
- Sildenafil Citrate IMD
- SAR-407899
- IK-7002
- Others
Applications
- Clinic
- Hospital
- Others
Companies covered
- Biolab Sanus Farmaceutica Ltda.
- Hanmi Pharmaceuticals, Co. Ltd.
- Ikaria Inc.
- Proreo Pharma AG
- Vectura Group plc
- Vicore Pharma AB
- Bayer AG
- Sanofi
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Pulmonary Hypertension Drug Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Pulmonary Hypertension Drug Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Pulmonary Hypertension Drug Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Pulmonary Hypertension Drug Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Pulmonary Hypertension Drug Market Dynamics
- 2.1 Pulmonary Hypertension Drug Industry Trends
- 2.2 Pulmonary Hypertension Drug Industry Drivers
- 2.3 Pulmonary Hypertension Drug Industry Opportunities and Challenges
- 2.4 Pulmonary Hypertension Drug Industry Restraints
3 Pulmonary Hypertension Drug Market by Manufacturers
- 3.1 Global Pulmonary Hypertension Drug Revenue by Manufacturers (2021-2026)
- 3.2 Global Pulmonary Hypertension Drug Sales by Manufacturers (2021-2026)
- 3.3 Global Pulmonary Hypertension Drug Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Pulmonary Hypertension Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Pulmonary Hypertension Drug Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Pulmonary Hypertension Drug Manufacturers, Product Type & Application
- 3.7 Global Pulmonary Hypertension Drug Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Pulmonary Hypertension Drug Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Pulmonary Hypertension Drug Players Market Share by Revenue in 2025
- 3.8.3 2025 Pulmonary Hypertension Drug Tier 1, Tier 2, and Tier 3
4 Pulmonary Hypertension Drug Market by Type
- 4.1 Pulmonary Hypertension Drug Type Introduction
- 4.1.1 IK-3001
- 4.1.2 Riociguat
- 4.1.3 Sildenafil Citrate IMD
- 4.1.4 SAR-407899
- 4.1.5 IK-7002
- 4.1.6 Others
- 4.2 Global Pulmonary Hypertension Drug Sales by Type
- 4.2.1 Global Pulmonary Hypertension Drug Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Pulmonary Hypertension Drug Sales by Type (2021-2032)
- 4.2.3 Global Pulmonary Hypertension Drug Sales Market Share by Type (2021-2032)
- 4.3 Global Pulmonary Hypertension Drug Revenue by Type
- 4.3.1 Global Pulmonary Hypertension Drug Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Pulmonary Hypertension Drug Revenue by Type (2021-2032)
- 4.3.3 Global Pulmonary Hypertension Drug Revenue Market Share by Type (2021-2032)
5 Pulmonary Hypertension Drug Market by Application
- 5.1 Pulmonary Hypertension Drug Application Introduction
- 5.1.1 Clinic
- 5.1.2 Hospital
- 5.1.3 Others
- 5.2 Global Pulmonary Hypertension Drug Sales by Application
- 5.2.1 Global Pulmonary Hypertension Drug Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Pulmonary Hypertension Drug Sales by Application (2021-2032)
- 5.2.3 Global Pulmonary Hypertension Drug Sales Market Share by Application (2021-2032)
- 5.3 Global Pulmonary Hypertension Drug Revenue by Application
- 5.3.1 Global Pulmonary Hypertension Drug Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Pulmonary Hypertension Drug Revenue by Application (2021-2032)
- 5.3.3 Global Pulmonary Hypertension Drug Revenue Market Share by Application (2021-2032)
6 Global Pulmonary Hypertension Drug Sales by Region
- 6.1 Global Pulmonary Hypertension Drug Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Pulmonary Hypertension Drug Sales by Region (2021-2032)
- 6.2.1 Global Pulmonary Hypertension Drug Sales by Region (2021-2026)
- 6.2.2 Global Pulmonary Hypertension Drug Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Pulmonary Hypertension Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Pulmonary Hypertension Drug Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Pulmonary Hypertension Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Pulmonary Hypertension Drug Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Pulmonary Hypertension Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Pulmonary Hypertension Drug Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Pulmonary Hypertension Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Pulmonary Hypertension Drug Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Pulmonary Hypertension Drug Revenue by Region
- 7.1 Global Pulmonary Hypertension Drug Revenue by Region
- 7.1.1 Global Pulmonary Hypertension Drug Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Pulmonary Hypertension Drug Revenue by Region (2021-2026)
- 7.1.3 Global Pulmonary Hypertension Drug Revenue by Region (2027-2032)
- 7.1.4 Global Pulmonary Hypertension Drug Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Pulmonary Hypertension Drug Revenue (2021-2032)
- 7.2.2 North America Pulmonary Hypertension Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Pulmonary Hypertension Drug Revenue (2021-2032)
- 7.3.2 Europe Pulmonary Hypertension Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Pulmonary Hypertension Drug Revenue (2021-2032)
- 7.4.2 Asia-Pacific Pulmonary Hypertension Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Pulmonary Hypertension Drug Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Pulmonary Hypertension Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Biolab Sanus Farmaceutica Ltda.
- 8.1.1 Biolab Sanus Farmaceutica Ltda. Company Information
- 8.1.2 Biolab Sanus Farmaceutica Ltda. Business Overview
- 8.1.3 Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Product Portfolio
- 8.1.5 Biolab Sanus Farmaceutica Ltda. Recent Developments
- 8.2 Hanmi Pharmaceuticals, Co. Ltd.
- 8.2.1 Hanmi Pharmaceuticals, Co. Ltd. Company Information
- 8.2.2 Hanmi Pharmaceuticals, Co. Ltd. Business Overview
- 8.2.3 Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Product Portfolio
- 8.2.5 Hanmi Pharmaceuticals, Co. Ltd. Recent Developments
- 8.3 Ikaria Inc.
- 8.3.1 Ikaria Inc. Company Information
- 8.3.2 Ikaria Inc. Business Overview
- 8.3.3 Ikaria Inc. Pulmonary Hypertension Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Ikaria Inc. Pulmonary Hypertension Drug Product Portfolio
- 8.3.5 Ikaria Inc. Recent Developments
- 8.4 Proreo Pharma AG
- 8.4.1 Proreo Pharma AG Company Information
- 8.4.2 Proreo Pharma AG Business Overview
- 8.4.3 Proreo Pharma AG Pulmonary Hypertension Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Proreo Pharma AG Pulmonary Hypertension Drug Product Portfolio
- 8.4.5 Proreo Pharma AG Recent Developments
- 8.5 Vectura Group plc
- 8.5.1 Vectura Group plc Company Information
- 8.5.2 Vectura Group plc Business Overview
- 8.5.3 Vectura Group plc Pulmonary Hypertension Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Vectura Group plc Pulmonary Hypertension Drug Product Portfolio
- 8.5.5 Vectura Group plc Recent Developments
- 8.6 Vicore Pharma AB
- 8.6.1 Vicore Pharma AB Company Information
- 8.6.2 Vicore Pharma AB Business Overview
- 8.6.3 Vicore Pharma AB Pulmonary Hypertension Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Vicore Pharma AB Pulmonary Hypertension Drug Product Portfolio
- 8.6.5 Vicore Pharma AB Recent Developments
- 8.7 Bayer AG
- 8.7.1 Bayer AG Company Information
- 8.7.2 Bayer AG Business Overview
- 8.7.3 Bayer AG Pulmonary Hypertension Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Bayer AG Pulmonary Hypertension Drug Product Portfolio
- 8.7.5 Bayer AG Recent Developments
- 8.8 Sanofi
- 8.8.1 Sanofi Company Information
- 8.8.2 Sanofi Business Overview
- 8.8.3 Sanofi Pulmonary Hypertension Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Sanofi Pulmonary Hypertension Drug Product Portfolio
- 8.8.5 Sanofi Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Pulmonary Hypertension Drug Value Chain Analysis
- 9.1.1 Pulmonary Hypertension Drug Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Pulmonary Hypertension Drug Production Mode & Process
- 9.2 Pulmonary Hypertension Drug Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Pulmonary Hypertension Drug Distributors
- 9.2.3 Pulmonary Hypertension Drug Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst